Featured Research

from universities, journals, and other organizations

Urologists Study Fluorescent Dye, Blue Light To Detect Bladder Tumors

Date:
January 25, 2005
Source:
University Of Rochester Medical Center
Summary:
One of the challenges urologic surgeons face when treating early bladder cancers is that they can’t see tiny tumors during procedures to remove larger tumors. Missing the tiny tumors increases the chances that the cancer could recur, sometimes as early as three months after treatment.

One of the challenges urologic surgeons face when treating early bladder cancers is that they can’t see tiny tumors during procedures to remove larger tumors. Missing the tiny tumors increases the chances that the cancer could recur, sometimes as early as three months after treatment.

Related Articles


Urologists at the James P. Wilmot Cancer Center are joining an international clinical study of a new photosensitizer – a liquid dye inserted into the bladder -- to improve detection of small tumors that will likely grow after surgery.

The photosensitizer, when placed in the bladder, makes cancer cells glow bright pink under a blue light. This makes it easier for surgeons to see and remove during cystoscopic procedures. A cystoscopy involves insertion of a thin, lighted instrument, a cystoscope, into the urethra and bladder for examination and tissue samples can be removed and examined.

Hexvix, or hexyl aminolevulinate, is similar to a chemical found naturally in the body and contains porphyrins. Cancer cells absorb this substance faster than healthy cells, and they turn fluorescent pink when the cystoscope light changes from white to blue.

“The change in color is dramatic and this lets us see tiny tumors or satellite tumors that we wouldn’t have seen before with traditional white lighting during cystoscopy,” says Edward M. Messing, M.D., urology chair, at the Wilmot Cancer Center at the University of Rochester Medical Center. The Wilmot Cancer Center is the only upstate New York site testing this new technique.

The randomized Phase III study of hexvix, the new drug, will enroll 620 people in the United States, Canada and Europe, including about 30 in Rochester. Hexvix, developed by PhotoCure ASA of Norway, is used in European countries and this study may open its use to patients in the United States. PhotoCure is funding this study.

The American Cancer Society estimates 60,240 new cases of bladder cancer will be diagnosed in the U.S. this year. Bladder cancer is more common among men than women and more common among whites than blacks. When found and treated early, the chances for survival are very good. About 12,710 Americans will die of the disease.


Story Source:

The above story is based on materials provided by University Of Rochester Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Rochester Medical Center. "Urologists Study Fluorescent Dye, Blue Light To Detect Bladder Tumors." ScienceDaily. ScienceDaily, 25 January 2005. <www.sciencedaily.com/releases/2005/01/050124011311.htm>.
University Of Rochester Medical Center. (2005, January 25). Urologists Study Fluorescent Dye, Blue Light To Detect Bladder Tumors. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2005/01/050124011311.htm
University Of Rochester Medical Center. "Urologists Study Fluorescent Dye, Blue Light To Detect Bladder Tumors." ScienceDaily. www.sciencedaily.com/releases/2005/01/050124011311.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins